Filter posts

Discrimination Against Vulnerable Patients Is Nothing New

Transformative therapies are advancing like never before, and a new class of medicines are changing …

Greenwood: In Pharma Value Chain, PBMs Manage to Benefit

Writing for The Hill, BIO’s President and CEO Jim Greenwood offered praise to the Senate Finance …

Peter Pitts Examines the Role of PBMs and their Deceptive Tactics

A piece by Peter J. Pitts, a former FDA Associate Commissioner and President of the …

The Administration’s Orwellian Defense of Importing Foreign Price Controls

The Trump administration is out with a new blog post defending its plan to adopt …

Think the Drug-Pricing debate addresses Patient Costs? Think again.

Writing for The Hill, BIO President and CEO Jim Greenwood tackled the drug pricing debate …

Hits to Patients Keep on Coming

At a time when prescription drug prices and spending are remarkably stable, patients are getting …

On the President’s Drug Cost Plan, Three Important Concerns

Part 3. Restricting access under Medicaid Is not the answer This week, BIO launched a …

On the President’s Drug Cost Plan, Three Important Concerns

Part 1. Restricting access under Medicare Part D  The Trump administration is out with its …

New Infographic Highlights the Remarkable Success of Medicare Part D

Since 2006, the Medicare prescription drug program – known as Medicare Part D – has …

A Flawed Bill That Would Harm Seniors

The Medicare prescription drug program has been a remarkable success for both seniors and taxpayers, …